Big last day of #APSAD40 today for #opioid research. I'll be presenting in a symposium of #naloxone today, and then super excited to chair two sessions on #overdose and prescription #opioid treatment ... a couple of highlights include ... 1/
3/ @DrTinaLam_AU (also from @MonashAddiction) presenting on prescription opioid overdose using emergency department data and @JMoullin from @CurtinUni talking about pharmacists and naloxone supply in Western Australia
4/@Ria_Hopkins talking about difficulties accessing prescription opioids (I may have the inside track on this one) - should be a great talk! and Isabella Natale
(Overdose Response Worker from @BarwonHealth) talking about barriers to naloxone supply for people in opioid treatment
5/ And if that isn't enough excitement, @cassjcw (ECR award winner for 2021) will be giving her keynote..
6/ I am not sure if I can mange live tweeting while chairing a session but I will give it a red hot go! If you are already registered for #APSAD40 I hope to see you in one of these sessions!
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Last session for me today at @APSAD40 on prescription opioids, treatment, and prescription drug monitoring programs. First up - a mini-symposium with @PPrathivadi , @LouisaPicco and @Sarah_Haines_ .. lets see if I can pull out a few key findings 1/
2/ First up @PPrathivadi talking about GPs use of PDMP, benefits for informing prescribing but challenges with reluctance to use technology - also check out this super commentary with @Sarah_Haines_ in the @AusJPrimHealth on evaluation considerations publish.csiro.au/py/PY20296
3/ Next is @LouisaPicco talking about implementation of prescription monitoring with #pharmacists. Alerts seem to really drive responses (over other clinical risk factors).. are automatic alerts replacing clinical judgement? Conclusion: PDMP should not replace clinical decisions
Last afternoon of #APSAD40! It is a joy to chair this session on #overdose - lots of key learnings and great work in the prevention space. Here are a couple of highlights from the session 1/
2/ Louisa Durrant (NUM at Melaleuca, @qldhealthnews) spoke about lessons learned supplying take-home naloxone in the opioid treatment program in QLD. Despite many having experienced an overdose, few had access to naloxone before the pilot, and consumers valued being offered THN.
3/ Dr Eleanor Black presented on the ONE study, a pilot study looking at ED delivery of #naloxone - a key opportunity to offer naloxone to people at risk of overdose. Most (not all) staff through they should offer #naloxone, with common misconception of naloxone increased OD risk
What's new in take-home #naloxone in Australia? 1/ Ange Matheson from @NSWHealth explains the NSW model which allows a whole range of workers and non-medical services across the NSW (e.g. those working NGOs without pharmacists or doctors on staff) to supply naloxone #APSAD40
2/ Tegan Nuckey from Queensland (QuIHN) talks about their #naloxone program, adapted from the WA model.. now funded until 2023 (but no recurrent funding). Hopefully a national program will be funded by then! No cost, script, no ID - addressing key barriers.
3/ Robin Greaves (Tasmania) presented on the Tasmanian gov program where poisons regulations were changed to allow supply by NPS workers as part of their pilot. With limited funding, the pilot focused on people who use heroin, now ongoing funding provides FREE naloxone from NSPs
It's that time of year again, when I score grant apps for much of the weekend, and late into the weeknights too. Again, as I do each year, I implore you, grant writers, please do not use lots of acronyms in your grants, and don't make up your own acronyms. 1/ #AcademicTwitter
2/ This is particularly so for multidisciplinary grants. It is impossible that a panel member will be expert in every discipline, and you would be surprised how many acronyms mean different things in different disciplines.
3/ If you need to use acronyms to jam more words onto your page, forming the dreaded 'wall of text' ... think again. No one thanks you for this. It is really hard to find the key points you are making when every square cm of every page is jammed-packed with text.
Advice from the DHHS about maintaining continuity for pharmacotherapy treatment is here. Key principals include writing prescriptions for longer (with regular phone check-ins with patients) and increased TA doses where clinically appropriate (1/3) bit.ly/3e4EpSu
Guidance to support assessing appropriateness for additional takeaways are here. Where clinically appropriate, increasing takeaways means that people can stay safe at home and travel pharmacies. #Naloxone is recommended with takeaways bit.ly/2UQgmiy (2/3)